Skip to main content
Premium Trial:

Request an Annual Quote

Aeterna Zentaris to Collaborate with Almac on Companion Dx

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Late-stage drug development company Aeterna Zentaris announced today that it plans to collaborate with the diagnostics division of Almac on research aimed at developing a companion diagnostic tool to complement its AEZS-108 compound.

The companies plan to come up with a companion diagnostic for assessing the expression of luteinizing hormone-releasing hormone — information that can be used to help guide treatment with AEZS-108, Aeterna Zentaris' LHRH-targeted conjugate with doxorubicin.

"This state of the art companion diagnostic tool will allow us to develop improved methods of selecting the most appropriate patients to be treated with AEZS-108 in order to enhance the efficiency of our clinical trials and help us with the future successful development of AEZS-108 in a number of different LHRH expressing cancers," Aeterna Zentaris President and CEO Juergen Engel said in a statement.

LHRH receptor expression has been linked to some ovarian, endometrial, breast, bladder, prostrate, and pancreatic cancers. At the moment, AEZS-108 is in Phase 2 trials for treating advanced ovarian and endometrial cancers that are LHRH receptor positive. AEZS-108 has also been designated an orphan drug by the US Food and Drug Administration and has investigational new drug status for bladder cancer in the US.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.